However, the eCOA/ePRO market has seen minimal innovation since the transition from paper-based forms to digital formats two decades ago, leaving a gap in meeting the escalating demand for improved patient reported outcomes driven by heightened regulatory requirements.
Speaking on the pressing need for industry-wide transformation, Steve Rosenberg, CEO of eCOA/ePRO provider uMotif, he said: “The failure of eCOA/ePRO technology to keep pace with market needs and expectations is impacting trial delivery and impeding the delivery of strategic value to sponsors and CROs.”
The impact of innovative eCOA solutions
Addressing this critical challenge, uMotif has made significant strides in revolutionizing eCOA/ePRO technology.
Rosenberg highlights the company's success, he said: “We're closing significant business deals, securing numerous trials, and Q2 is shaping up to be even better. We're really making great progress.”
A pivotal collaboration driving innovation in the field is uMotif's partnership with MoCA Cognition, introducing pioneering tools for capturing cognitive function and eCOA/ePRO data in CNS research.
uMotif's collaboration with MoCA cognition
Dr. Ziad Nasreddine, CEO of MoCA Cognition, underscores the impact of their collaboration, stating: “Delivering a patient-centric approach to capturing cognitive function and other outcome measures has diverse applications, offering a unique approach to clinical trial recruitment, screening, and data capture.”
The collaboration introduces the MoCA XpressO test, a self-administered, digital cognitive pre-screening tool designed to efficiently distinguish between populations of subjective vs. objective cognitive impairment. When integrated with the standard MoCA test, these tools enable the comprehensive capture of eCOA/ePRO data for screening, reducing screen fail rates and accelerating study timelines.
Rosenberg emphasizes the significance of this collaboration, he added: “Through our partnership with MoCA Cognition, we are empowering sponsors, CROs, sites, and patients with the combined power of modern eCOA/ePRO and groundbreaking cognitive tools that deliver measurable improvements in patient engagement and data quality in the critical area of CNS research.”
The combined power of modern eCOA/ePRO and cognitive tools
The integration of innovative eCOA/ePRO solutions, such as those developed by uMotif and MoCA Cognition, represents a substantial leap toward addressing the longstanding need for advancements in clinical trial data capture. With a focus on enhancing patient engagement, data quality, and overall trial efficiency, these advancements are positioned to drive positive transformations in the field of clinical research.
As the industry moves forward, it is imperative for key stakeholders to recognize the significance of continuous innovation in eCOA/ePRO technology. With uMotif and MoCA Cognition leading the way, the field is poised to witness significant enhancements in the capture of patient data and the overall conduct of clinical trials, ultimately benefiting the advancement of medical treatments and therapies.
